US20110054015A1 - Solid forms of ortataxel - Google Patents

Solid forms of ortataxel Download PDF

Info

Publication number
US20110054015A1
US20110054015A1 US12/863,167 US86316709A US2011054015A1 US 20110054015 A1 US20110054015 A1 US 20110054015A1 US 86316709 A US86316709 A US 86316709A US 2011054015 A1 US2011054015 A1 US 2011054015A1
Authority
US
United States
Prior art keywords
ortataxel
process according
water
ethanol
mixtures
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/863,167
Inventor
Daniele Ciceri
Nicola Sardone
Bruno Gabetta
Maurizio Ricotti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Indena SpA
Original Assignee
Indena SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indena SpA filed Critical Indena SpA
Assigned to INDENA S.P.A. reassignment INDENA S.P.A. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CICERI, DANIELE, GABETTA, BRUNO, RICOTTI, MAURIZIO, SARDONE, NICOLA
Publication of US20110054015A1 publication Critical patent/US20110054015A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D305/06—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems

Definitions

  • the present invention relates to solid forms of Ortataxel (13-(N-Boc- ⁇ -isobutylserinyl)-14- ⁇ -hydroxybaccatin III 1,14-carbonate) (1), mixtures thereof and methods for their preparation.
  • Ortataxel (1) is an antitumor compound particularly active against breast, lung, ovary, colon, prostate, kidney and pancreas tumors, even in case of resistance to known antitumor agents such as adriamycin, vinblastine and some platinum derivatives.
  • Ortataxel can be prepared according to the methods described in U.S. Pat. No. 7,232,916, in U.S. Pat. No. 6,737,534 and in U.S. Pat. No. 6,906,101. These patents disclose in the examples a final purification step consisting of crystallization from a mixture of acetone and hexane, which gives Ortataxel in the form of a solvate with an acetone content ranging from 4.5 to 6.5%.
  • the XRPD of the acetone solvate shows distinctive peaks at approximately 7.9, 9.8, 10.6, 10.9, 14.6, 16.9, 19.7, 21.3 deg 2-theta.
  • the DSC curve shows an endothermic peak with onset at about 164° C. due to melting and release of the crystallization solvent (confirmed by a weight loss of about 5.0% in TG/DTA) and a weak exothermic peak with maximum at about 212° C. followed by an intense endothermic peak with maximum at about 247° C. due to melting and incipient decomposition.
  • the IR shows characteristic absorption frequencies at 3521, 3321, 2971, 2953, 1826, 1762, 1706, 1526, 1366, 1238, 1165, 1072, 723 cm ⁇ 1 .
  • Form A is an amorphous solid, since it shows an X-ray powder diffraction pattern with no discernable peaks. It can be easily prepared from Ortataxel, for example Ortataxel acetone solvate obtained according to the synthetic procedures described in the above-cited patents, by dissolution in a suitable water-miscible solvent, followed by fast addition of water containing traces (usually 0.001-0.003% w/v) of an organic acid such as acetic or ascorbic acid, preferably citric.
  • Suitable water-miscible solvent means a ketone or an aprotic dipolar solvent or a mixture thereof; preferred solvents are acetone, dimethylsulfoxide and mixtures thereof.
  • the process is usually carried out at a temperature ranging from 20 to 30° C.; and the preferred organic acid is citric acid.
  • the organic acid avoids undesired formation of the 7-epimer and makes Form A physically and chemically stable for at least 36 months.
  • the preparation of Form A is carried out dissolving Ortataxel in acetone (8 mL/g ortataxel ) and precipitating it with a water (40 mL/g ortataxel ) containing 0.001-0.003% w/v citric acid, at room temperature.
  • Form B is a crystalline polymorph melting at 159° C.; with respect to the pseudopolymorhic acetone solvate, Form B is characterized by a low solvent content, ease of isolation by filtration or centrifugation and chemical and physical stability for at least 36 months.
  • Form B can be prepared dissolving Ortataxel, for example the acetone solvate or the above form A, in a protic organic solvent, such as methanol, ethanol or isopropanol, preferably ethanol, containing traces of an organic acid (0.01-0.03% w/v), such as acetic, ascorbic but preferably citric acid, followed by addition of water until precipitation and stirring the resulting mixture at a temperature ranging from 0 to 60° C., preferably at 40° C., for a time ranging from 4 to 8 hours.
  • a protic organic solvent such as methanol, ethanol or isopropanol, preferably ethanol, containing traces of an organic acid (0.01-0.03% w/v), such as acetic, ascorbic but preferably citric acid, followed by addition of water until precipitation and stirring the resulting mixture at a temperature ranging from 0 to 60° C., preferably at 40° C., for a time ranging from 4 to 8 hours.
  • the preparation of Form B is carried out dissolving Ortataxel in ethanol (8-12 mL/g ortataxel ) containing 0.01-0.03% w/v of citric acid, followed by addition of water (13-20 mL/g ortataxel ), so that the ethanol/water ratio ranges between 0.5-0.7, and stirring for 6 hours. If stirring is carried out for less than 4 hours, Ortataxel is obtained as a mixture of Form A and Form.
  • Ortataxel Forms A and B and mixtures thereof can advantageously be used for the preparation of pharmaceutical compositions for the treatment of cancer.
  • mixtures of form A and B which have different bioavailabilities, are useful for the preparation of controlled-release solid Forms. Therefore, a further object of the present invention are pharmaceutical compositions containing Ortataxel crystalline Form A or B or mixtures thereof in admixture with pharmaceutically acceptable carriers and/or ingredients, for example those disclosed in “Remington's Pharmaceutical Sciences”, Mack Publishing Co., N.Y., USA.
  • XRPD X-ray powder diffraction
  • DSC differential scanning calorimetry
  • TG/DTA thermogravimetric/differential thermal analyses
  • IR infrared
  • optical microscopy was used to characterize the new solid Forms which are compared with the analytical data of the acetone solvate.
  • FIGS. 1-4 XRPD, DSC, TG/DTA and IR spectra of Form A;
  • FIGS. 5-8 XRPD, DSC, TG/DTA and IR spectra of Form B;
  • FIGS. 9-12 XRPD, DSC, TG/DTA and IR spectra of a mixture of Form A and Form B, containing about 75% of Form B;
  • FIG. 13 DSC profile of different proportions of Form A and Form B.
  • the x-ray powder diffraction pattern of Form A ( FIG. 1 ) is typical for an amorphous product with complete absence of diffraction peaks.
  • the DSC curve of Form A shows a weak and broad endothermic signal with maximum at about 80° C., a baseline deflection due to T g between 133° C. and 143° C., an exothermic peak with maximum at about 214° C. due to recrystallisation of the melted product and the consequent melting peak with maximum at about 246° C. followed by decomposition.
  • the IR spectrum of Form A ( FIG. 3 ) shows the characteristic absorption frequencies at 3442, 2960, 1821, 1732, 1714, 1368, 1236, 1162, 1085, 1068, 984, 907, 776, 763, 711 cm ⁇ 1 .
  • the TG/DT analysis of Form A confirms the DSC analysis showing a DT profile characterized by a baseline deflection due to T g between 130° C. and 143° C., an exothermic peak with maximum at about 211° C. due to recrystallisation of the melted product and the consequent melting peak with maximum at about 249° C. followed by decomposition.
  • the TG profile shows a weight loss of about 1.0% from 30 to 150° C. due to release of residual moisture and a weight loss of about 1.6% which takes place upon recrystallisation followed by a massive weight loss due to a degradative reaction.
  • the optical microscopy shows that solid Form A is constituted by a glassy irregular particulate with a large variety of dimensions and absence of well-shaped crystal Forms.
  • the x-ray powder diffraction pattern of Form B ( FIG. 5 ) shows a crystalline structure with useful distinctive peaks at approximately 3.5, 6.8, 9.9, 10.1, 10.7, 12.1, 13.1, 14.8, 18.2, 19.7, 21.3, 29.3 deg 2-theta.
  • the DSC curve of Form B ( FIG. 6 ) shows a weak and broad endothermic signal with maximum below 100° C., a first melting peak with maximum at about 166° C. and ⁇ H fus of about ⁇ 20 J/g, an exothermic peak with maximum at about 196° C. due to recrystallisation of the melted product and a second melting peak with maximum at about 252° C. followed by decomposition.
  • FIG. 7 shows the characteristic absorption frequencies at 3444, 2961, 1816, 1735, 1720, 1689, 1368, 1237, 1163, 1085, 1068, 1047, 989, 949, 907, 776, 764, 710 cm ⁇ 1 .
  • the TG/DT analysis of Form B confirms the DSC analysis showing a weak and broad endothermic signal with maximum below 100° C. due to release of residual moisture, a first melting peak with maximum at about 164° C., an exothermic peak with maximum at about 200° C. due to recrystallisation of the melted product and a second melting peak with maximum at about 253° C. followed by decomposition.
  • a weight loss of about 1.4% from 30 to 150° C. due to release of residual moisture is followed by a massive weight loss which takes place above 240° C. due to a degradative reaction.
  • the optical microscopy shows that solid Form B is constituted by acicular (needle-like) crystals.
  • the x-ray powder diffraction pattern of the mixture of Form A and Form B shows a crystalline structure with distinctive peaks at approximately 3.4, 6.8, 9.9, 10.6, 12.1, 13.1, 14.8, 18.1, 19.7, 21.2 deg 2-theta due to the fraction of Form B in the mixture.
  • the DSC curve ( FIG. 10 ) shows a weak and broad endothermic signal with maximum below 100° C., a first melting peak with maximum at about 163° C. and ⁇ H fus of about ⁇ 15 J/g, an exothermic peak with maximum at about 202° C. due to recrystallisation of the melted product and a second melting peak with maximum at about 251° C. followed by decomposition.
  • the IR spectrum ( FIG. 11 ) shows characteristic absorption frequencies at 3448, 2960, 1816, 1735, 1719, 1688, 1368, 1237, 1164, 1085, 1068, 1048, 989, 949, 906, 776, 764, 710 cm ⁇ 1 .
  • the TG/DT analysis confirms the DSC analysis showing a weak and broad endothermic signal with maximum below 100° C. due to release of residual moisture, a first melting peak with maximum at about 162° C., an exothermic peak with maximum at about 202° C. due to recrystallisation of the melted product and a second melting peak with maximum at about 250° C., followed by decomposition.
  • a weight loss of about 2.7% from 30 to 150° C. due to release of residual moisture is followed by a massive weight loss which takes place at 240° C. due to a degradative reaction.
  • Optical microscopy shows that the Mixture of Form A and Form B is constituted by prismatic crystals.
  • X-ray powder diffraction patterns were collected on a Philips PW1800 diffractometer.
  • the x-ray generator was operated at 45 kV and 40 mA, using the Cu K ⁇ line as radiation source.
  • the sample was packed on a suitable slit and the irradiated length was 10 mm.
  • the data were collected between 2 and 65 deg 2-theta with a step size of 0.02 deg 2-theta.
  • the analyses were performed using a Seiko TG/DTA6200 simultaneous system using open aluminum pans (40 ⁇ l volume).
  • the TG/DT signals were recorded from 30 to 300° C. with linear heating rate (10° C./min) under a 200 ml/min nitrogen flow. About 10 mg of powder was used for each measurement.
  • the infrared spectra were recorded with ATR technique using a Fourier-transform spectrometer Perkin Elmer Spectrum One.
  • the spectra were the result of the acquisition and transformation of 16 co-added scans in the 4000-550 cm ⁇ 1 spectral region at a resolution of 4 cm ⁇ 1 .
  • the analyses were performed using a transmitted-light microscope Zeiss Axioskop. For each analysis a little amount of sample was dispersed in silicone oil, mounted on a specimen slide and covered with a micro cover glass. The observations were carried out under appropriate conditions of illumination, contrast and magnification.
  • FIG. 13 shows the DSC analysis of the samples compared to the curve of pure Form B.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epoxy Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

The present invention relates to solid forms of 13-(N-Boc-β-isobutylserinyl)-14-β-hydroxybaccatin III 1,14-carbonate (Ortataxel). Amorphous Form A, crystalline Form B, mixtures thereof and processes for preparing them are disclosed. Amorphous Form A is prepared by fast precipitation of Ortataxel from a mixture of acetone and water. Form A transforms in Form B when suspended and stirred in a mixture of ethanol and water for 4-8 hours. If the suspension is stirred for less than 4 hours, mixtures of Form B and Form A are obtained. Form B or mixtures of Forms A and B can also be obtained dissolving Ortataxel in a protic organic solvent, followed by addition of water.

Description

    FIELD OF THE INVENTION
  • The present invention relates to solid forms of Ortataxel (13-(N-Boc-β-isobutylserinyl)-14-β-hydroxybaccatin III 1,14-carbonate) (1), mixtures thereof and methods for their preparation.
  • Figure US20110054015A1-20110303-C00001
    • BACKGROUND OF THE INVENTION
  • Ortataxel (1) is an antitumor compound particularly active against breast, lung, ovary, colon, prostate, kidney and pancreas tumors, even in case of resistance to known antitumor agents such as adriamycin, vinblastine and some platinum derivatives.
  • Figure US20110054015A1-20110303-C00002
  • Ortataxel can be prepared according to the methods described in U.S. Pat. No. 7,232,916, in U.S. Pat. No. 6,737,534 and in U.S. Pat. No. 6,906,101. These patents disclose in the examples a final purification step consisting of crystallization from a mixture of acetone and hexane, which gives Ortataxel in the form of a solvate with an acetone content ranging from 4.5 to 6.5%.
  • The XRPD of the acetone solvate shows distinctive peaks at approximately 7.9, 9.8, 10.6, 10.9, 14.6, 16.9, 19.7, 21.3 deg 2-theta. The DSC curve shows an endothermic peak with onset at about 164° C. due to melting and release of the crystallization solvent (confirmed by a weight loss of about 5.0% in TG/DTA) and a weak exothermic peak with maximum at about 212° C. followed by an intense endothermic peak with maximum at about 247° C. due to melting and incipient decomposition. The IR shows characteristic absorption frequencies at 3521, 3321, 2971, 2953, 1826, 1762, 1706, 1526, 1366, 1238, 1165, 1072, 723 cm−1.
  • It is well known that volatile impurities in active pharmaceutical ingredients must comply with ICH (International Conference on Harmonisation) guidelines (Q3C); in this specific case an acetone content from 4.5 to 6.5% would not be allowed. Thus, it would be desirable to find a stable crystalline form of Ortataxel which does not contain residual solvents in amounts unacceptable from a regulatory point of view. Such crystalline form should also be chemically and thermodynamically stable, i.e. it should keep the same quality during storage, and should be obtainable through a reproducible method.
    • DISCLOSURE OF THE INVENTION
  • It has now been found that Ortataxel exists in two non-solvated physical Forms, herein after referred to as Forms A and B, which can also be obtained as mixtures.
  • Form A is an amorphous solid, since it shows an X-ray powder diffraction pattern with no discernable peaks. It can be easily prepared from Ortataxel, for example Ortataxel acetone solvate obtained according to the synthetic procedures described in the above-cited patents, by dissolution in a suitable water-miscible solvent, followed by fast addition of water containing traces (usually 0.001-0.003% w/v) of an organic acid such as acetic or ascorbic acid, preferably citric. “Suitable water-miscible solvent” means a ketone or an aprotic dipolar solvent or a mixture thereof; preferred solvents are acetone, dimethylsulfoxide and mixtures thereof. The process is usually carried out at a temperature ranging from 20 to 30° C.; and the preferred organic acid is citric acid. The organic acid avoids undesired formation of the 7-epimer and makes Form A physically and chemically stable for at least 36 months. According to a preferred embodiment, the preparation of Form A is carried out dissolving Ortataxel in acetone (8 mL/gortataxel) and precipitating it with a water (40 mL/gortataxel) containing 0.001-0.003% w/v citric acid, at room temperature.
  • Form B is a crystalline polymorph melting at 159° C.; with respect to the pseudopolymorhic acetone solvate, Form B is characterized by a low solvent content, ease of isolation by filtration or centrifugation and chemical and physical stability for at least 36 months. Form B can be prepared dissolving Ortataxel, for example the acetone solvate or the above form A, in a protic organic solvent, such as methanol, ethanol or isopropanol, preferably ethanol, containing traces of an organic acid (0.01-0.03% w/v), such as acetic, ascorbic but preferably citric acid, followed by addition of water until precipitation and stirring the resulting mixture at a temperature ranging from 0 to 60° C., preferably at 40° C., for a time ranging from 4 to 8 hours. According to a preferred embodiment, the preparation of Form B is carried out dissolving Ortataxel in ethanol (8-12 mL/gortataxel) containing 0.01-0.03% w/v of citric acid, followed by addition of water (13-20 mL/gortataxel), so that the ethanol/water ratio ranges between 0.5-0.7, and stirring for 6 hours. If stirring is carried out for less than 4 hours, Ortataxel is obtained as a mixture of Form A and Form.
  • Ortataxel Forms A and B and mixtures thereof can advantageously be used for the preparation of pharmaceutical compositions for the treatment of cancer. In particular, mixtures of form A and B, which have different bioavailabilities, are useful for the preparation of controlled-release solid Forms. Therefore, a further object of the present invention are pharmaceutical compositions containing Ortataxel crystalline Form A or B or mixtures thereof in admixture with pharmaceutically acceptable carriers and/or ingredients, for example those disclosed in “Remington's Pharmaceutical Sciences”, Mack Publishing Co., N.Y., USA.
  • The invention is now illustrated in greater detail in the following experimental section.
    • EXPERIMENTAL SECTION Description of the Figures
  • X-ray powder diffraction (XRPD), differential scanning calorimetry (DSC), thermogravimetric/differential thermal analyses (TG/DTA), infrared (IR), and optical microscopy were used to characterize the new solid Forms which are compared with the analytical data of the acetone solvate.
  • FIGS. 1-4: XRPD, DSC, TG/DTA and IR spectra of Form A;
  • FIGS. 5-8: XRPD, DSC, TG/DTA and IR spectra of Form B;
  • FIGS. 9-12: XRPD, DSC, TG/DTA and IR spectra of a mixture of Form A and Form B, containing about 75% of Form B;
  • FIG. 13: DSC profile of different proportions of Form A and Form B.
    •
  • Form A
  • The x-ray powder diffraction pattern of Form A (FIG. 1) is typical for an amorphous product with complete absence of diffraction peaks.
  • The DSC curve of Form A (FIG. 2) shows a weak and broad endothermic signal with maximum at about 80° C., a baseline deflection due to Tg between 133° C. and 143° C., an exothermic peak with maximum at about 214° C. due to recrystallisation of the melted product and the consequent melting peak with maximum at about 246° C. followed by decomposition.
  • The IR spectrum of Form A (FIG. 3) shows the characteristic absorption frequencies at 3442, 2960, 1821, 1732, 1714, 1368, 1236, 1162, 1085, 1068, 984, 907, 776, 763, 711 cm−1.
  • The TG/DT analysis of Form A (FIG. 4) confirms the DSC analysis showing a DT profile characterized by a baseline deflection due to Tg between 130° C. and 143° C., an exothermic peak with maximum at about 211° C. due to recrystallisation of the melted product and the consequent melting peak with maximum at about 249° C. followed by decomposition. The TG profile shows a weight loss of about 1.0% from 30 to 150° C. due to release of residual moisture and a weight loss of about 1.6% which takes place upon recrystallisation followed by a massive weight loss due to a degradative reaction.
  • The optical microscopy shows that solid Form A is constituted by a glassy irregular particulate with a large variety of dimensions and absence of well-shaped crystal Forms.
  • Form B
  • The x-ray powder diffraction pattern of Form B (FIG. 5) shows a crystalline structure with useful distinctive peaks at approximately 3.5, 6.8, 9.9, 10.1, 10.7, 12.1, 13.1, 14.8, 18.2, 19.7, 21.3, 29.3 deg 2-theta.
  • The DSC curve of Form B (FIG. 6) shows a weak and broad endothermic signal with maximum below 100° C., a first melting peak with maximum at about 166° C. and ΔHfus of about −20 J/g, an exothermic peak with maximum at about 196° C. due to recrystallisation of the melted product and a second melting peak with maximum at about 252° C. followed by decomposition.
  • The IR spectrum of Form B (FIG. 7 shows the characteristic absorption frequencies at 3444, 2961, 1816, 1735, 1720, 1689, 1368, 1237, 1163, 1085, 1068, 1047, 989, 949, 907, 776, 764, 710 cm−1.
  • The TG/DT analysis of Form B (FIG. 8) confirms the DSC analysis showing a weak and broad endothermic signal with maximum below 100° C. due to release of residual moisture, a first melting peak with maximum at about 164° C., an exothermic peak with maximum at about 200° C. due to recrystallisation of the melted product and a second melting peak with maximum at about 253° C. followed by decomposition. In the TG profile, a weight loss of about 1.4% from 30 to 150° C. due to release of residual moisture is followed by a massive weight loss which takes place above 240° C. due to a degradative reaction.
  • The optical microscopy shows that solid Form B is constituted by acicular (needle-like) crystals.
  • Mixture of Form A and Form B
  • The x-ray powder diffraction pattern of the mixture of Form A and Form B (FIG. 9) shows a crystalline structure with distinctive peaks at approximately 3.4, 6.8, 9.9, 10.6, 12.1, 13.1, 14.8, 18.1, 19.7, 21.2 deg 2-theta due to the fraction of Form B in the mixture.
  • The DSC curve (FIG. 10) shows a weak and broad endothermic signal with maximum below 100° C., a first melting peak with maximum at about 163° C. and ΔHfus of about −15 J/g, an exothermic peak with maximum at about 202° C. due to recrystallisation of the melted product and a second melting peak with maximum at about 251° C. followed by decomposition.
  • The IR spectrum (FIG. 11) shows characteristic absorption frequencies at 3448, 2960, 1816, 1735, 1719, 1688, 1368, 1237, 1164, 1085, 1068, 1048, 989, 949, 906, 776, 764, 710 cm−1.
  • The TG/DT analysis (FIG. 12) confirms the DSC analysis showing a weak and broad endothermic signal with maximum below 100° C. due to release of residual moisture, a first melting peak with maximum at about 162° C., an exothermic peak with maximum at about 202° C. due to recrystallisation of the melted product and a second melting peak with maximum at about 250° C., followed by decomposition. In the TG profile, a weight loss of about 2.7% from 30 to 150° C. due to release of residual moisture is followed by a massive weight loss which takes place at 240° C. due to a degradative reaction.
  • Optical microscopy shows that the Mixture of Form A and Form B is constituted by prismatic crystals.
  • These data clearly indicate that polymorphic Forms A and B of Ortataxel are easy distinguishable from the pseudopolymorphic acetone solvate by means of XRPD, DSC, IR and analyses for the solvent content (such as thermogravimetry or gas-chromatography).
  • Materials and Methods
  • X-Ray Powder Diffraction Pattern (xrpd)
  • X-ray powder diffraction patterns were collected on a Philips PW1800 diffractometer. The x-ray generator was operated at 45 kV and 40 mA, using the Cu Kα line as radiation source. The sample was packed on a suitable slit and the irradiated length was 10 mm. The data were collected between 2 and 65 deg 2-theta with a step size of 0.02 deg 2-theta.
  • Differential Scanning Calorimetry (DSC)
  • Measurements of differential scanning calorimetry were performed using a Mettler TC15 System equipped with a DSC20 measuring cell, using closed aluminum crucibles (40 μl volume) with a pinhole. Heat flow was recorded from 30 to 300° C. with a linear heating rate of 10° C./min under a 50 ml/min nitrogen flow. About 5 mg of powder was used for each measurement.
  • Thermogravimetry and Differential Thermal Analysis (TG/DTA)
  • The analyses were performed using a Seiko TG/DTA6200 simultaneous system using open aluminum pans (40 μl volume). The TG/DT signals were recorded from 30 to 300° C. with linear heating rate (10° C./min) under a 200 ml/min nitrogen flow. About 10 mg of powder was used for each measurement.
  • Fourier Transform Infrared Spectroscopy (FTIR)
  • The infrared spectra were recorded with ATR technique using a Fourier-transform spectrometer Perkin Elmer Spectrum One. The spectra were the result of the acquisition and transformation of 16 co-added scans in the 4000-550 cm−1 spectral region at a resolution of 4 cm−1.
  • Optical Microscopy
  • The analyses were performed using a transmitted-light microscope Zeiss Axioskop. For each analysis a little amount of sample was dispersed in silicone oil, mounted on a specimen slide and covered with a micro cover glass. The observations were carried out under appropriate conditions of illumination, contrast and magnification.
    • EXAMPLE 1 Preparation of Form A
  • Ortataxel (13 g) was dissolved in acetone (112.5 mL). Purified water (555 mL) containing citric acid (12 mg) was rapidly added under stirring, causing the precipitation of an amorphous solid which was filtered and washed with water (65 mL) containing citric acid (18 mg). The sample was dried at 40° C. for 48 hours affording 12 g of a white solid having the characteristic XRPD, DSC, IR and TG/DTA reported in FIGS. 1-4 respectively.
    • EXAMPLE 2 Preparation of Form B
  • Ortataxel (14 g) was dissolved in 95% ethanol (168 mL) containing citric acid (28 mg) at 50° C. Cold demineralised water (280 mL) was added to the resulting solution over 15 minutes. The suspension was stirred at 40° C. for 6 hours. The mixture was cooled down to 20° C. and the white solid was filtered off. The solid was washed with a solution of ethanol (168 mL) and water (280 mL). The solid was dried under vacuum at 50° C. for 40 hours affording 13.4 g of a white solid having the characteristic XRPD, DSC, IR and TG/DTA reported in FIGS. 5-8 respectively.
    • EXAMPLE 3 Preparation of a Mixture of about 25% Form A and 75% Form B
  • Ortataxel (14 g) was dissolved in 95% ethanol (168 mL) containing citric acid (28 mg) at 50° C. Cold demineralised water (280 mL) was added to the resulting solution over 15 minutes. The mixture was promptly cooled down to 20° C. and the white solid was filtered off. The solid was washed with a solution of ethanol (168 mL) and water (280 mL) containing citric acid (25 mg). The solid was dried under vacuum at 50° C. for 40 hours affording 13.4 g of white material having the characteristic XRPD, DSC, IR and TG/DTA reported in FIGS. 9-12 respectively.
    • EXAMPLE 4 Preparation of Mixtures of Form A and Form B in Various Proportions
  • Form A (1 g) was suspended in a mixture of 95% ethanol (12 mL) and water (20 mL) containing citric acid (2 mg) at 40° C. Samples were taken at different times (t=0, t=5 min, t=30 min, t=6 h) in order to demonstrate that different proportions of Form A and Form B can be obtained. FIG. 13 shows the DSC analysis of the samples compared to the curve of pure Form B.

Claims (21)

1. Ortataxel [13-(N-Boc-β-isobutylserinyl)-14-β-hydroxybaccatin III 1,14-carbonate] (1)
Figure US20110054015A1-20110303-C00003
amorphous Form A.
2. Process for preparing amorphous Form A of claim 1, which comprises dissolving Ortataxel in a ketone or in an aprotic dipolar organic solvent, followed by addition of water containing 0.001-0.003% w/v of an organic acid.
3. The process according to claim 2 wherein the solvent is acetone or dimethylsulfoxide.
4. The process according to claim 2 or 3 wherein the organic acid is citric or ascorbic acid.
5. The process according to claim 3 wherein the organic acid is citric acid.
6. Ortataxel [13-(N-Boc-β-isobutylserinyl)-14-β-hydroxybaccatin III 1,14-carbonate] (1)
Figure US20110054015A1-20110303-C00004
crystalline Form B of having the XRPD characterized by the following peaks 3.5, 6.8, 9.9, 10.1, 10.7, 12.1, 13.1, 14.8, 18.2, 19.7, 21.3, 29.3 deg 2-theta.
7. A process for the preparation of Ortataxel Form B of claim 6, which comprises dissolving Ortataxel in ethanol containing traces of an organic acidic, followed by addition of water and stirring at a temperature ranging from 0 to 60° C. for a time ranging from 4 to 8 hours.
8. The process of claim 7 wherein the Ortataxel dissolved in ethanol is Ortataxel acetone solvate or Ortataxel form A as defined in claim 1.
9. The process according to claim 7 or 8 wherein the temperature is 40° C.
10. The process according to claim 9 wherein stirring is carried out for 6 hours.
11. The process according to any one of claims 8 to 10 wherein the organic acid is citric acid.
12. Mixtures of Ortataxel Form A as defined in claim 1 and Form B as defined in claim 6.
13. A mixture as defined in claim 12 wherein the amount of Form B is about 75% by weight.
14. A process for the preparation of the mixtures of Form A and Form B as defined in claim 12 or 13, which comprises suspending Ortataxel in a mixture of ethanol and water containing an organic acid and stirring for less than 4 hours and at a temperature ranging from 0 to 60° C.
15. The process according to claim 14 wherein the Ortataxel suspended in the mixture of ethanol and water is Ortataxel acetone solvate or Ortataxel Form A.
16. The process according to claim 15 wherein ethanol and water are in a 0.5-0.7 ratio.
17. The process according to claim 16 wherein the temperature is 40° C.
18. The process according to any one of claims 15-17 wherein the organic acid is citric acid or ascorbic acid.
19. The process according to claim 18 wherein the organic acid is citric acid.
20. Pharmaceutical compositions containing Ortataxel amorphous form A as defined in claim 1 or Ortataxel crystalline form B as defined in claim 5 or mixtures thereof as defined in claim 12 or 13 in admixture with suitable excipients and/or carriers.
21. Use of Ortataxel amorphous form A as defined in claim 1 or of Ortataxel crystalline form B as defined in claim 6 or of mixtures thereof as defined in claim 12 or 13 for the preparation of pharmaceutical compositions for the treatment of cancer.
US12/863,167 2008-01-18 2009-01-12 Solid forms of ortataxel Abandoned US20110054015A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08000904.6 2008-01-18
EP08000904A EP2080764B1 (en) 2008-01-18 2008-01-18 Solid forms of ortataxel
PCT/EP2009/000112 WO2009090024A1 (en) 2008-01-18 2009-01-12 Solid forms of ortataxel

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/000112 A-371-Of-International WO2009090024A1 (en) 2008-01-18 2009-01-12 Solid forms of ortataxel

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/102,365 Continuation US9127018B2 (en) 2008-01-18 2013-12-10 Solid forms of ortataxel

Publications (1)

Publication Number Publication Date
US20110054015A1 true US20110054015A1 (en) 2011-03-03

Family

ID=39205210

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/863,167 Abandoned US20110054015A1 (en) 2008-01-18 2009-01-12 Solid forms of ortataxel
US14/102,365 Expired - Fee Related US9127018B2 (en) 2008-01-18 2013-12-10 Solid forms of ortataxel

Family Applications After (1)

Application Number Title Priority Date Filing Date
US14/102,365 Expired - Fee Related US9127018B2 (en) 2008-01-18 2013-12-10 Solid forms of ortataxel

Country Status (19)

Country Link
US (2) US20110054015A1 (en)
EP (1) EP2080764B1 (en)
JP (1) JP2011509957A (en)
KR (1) KR101583098B1 (en)
CN (1) CN101952297A (en)
AR (1) AR070185A1 (en)
AU (1) AU2009204559B2 (en)
BR (1) BRPI0906698A2 (en)
CA (1) CA2711690C (en)
DK (1) DK2080764T3 (en)
ES (1) ES2389518T3 (en)
HK (1) HK1131782A1 (en)
IL (1) IL207045A (en)
MX (1) MX2010007850A (en)
NO (1) NO342387B1 (en)
RU (1) RU2488586C2 (en)
TW (1) TWI432437B (en)
WO (1) WO2009090024A1 (en)
ZA (1) ZA201004507B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9127018B2 (en) 2008-01-18 2015-09-08 Indena S.P.A. Solid forms of ortataxel

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104650109B (en) * 2013-11-22 2019-01-01 江苏天士力帝益药业有限公司 Bearing taxanes

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5319112A (en) * 1992-08-18 1994-06-07 Virgnia Tech Intellectual Properties, Inc. Method for the conversion of cephalomannine to taxol and for the preparation of N-acyl analogs of taxol
US5367086A (en) * 1992-03-13 1994-11-22 University Of Florida Process for the preparation of taxol and 10-deacetyltaxol
US6737534B2 (en) * 2000-11-28 2004-05-18 Indena S.P.A. Process for the preparation of taxan derivatives
US6906101B1 (en) * 1999-07-06 2005-06-14 Indena S.P.A. Taxane derivatives and processes for the preparation thereof
US7232916B1 (en) * 2006-05-11 2007-06-19 Indena S.P.A. Process for the preparation of a taxane derivative
US20070212394A1 (en) * 2006-03-10 2007-09-13 Cook Incorporated Taxane coatings for implantable medical devices

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3938480A1 (en) 1989-11-20 1991-05-23 Hell Rudolf Dr Ing Gmbh DEVICE FOR UNLOCKING SHEET RECORDING MATERIAL
US5380916A (en) 1990-11-02 1995-01-10 University Of Florida Method for the isolation and purification of taxane derivatives
MX9102128A (en) 1990-11-23 1992-07-08 Rhone Poulenc Rorer Sa DERIVATIVES OF TAXANE, PROCEDURE FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM
IT1254517B (en) 1992-03-06 1995-09-25 Indena Spa 14-BETA IDROSSI-10-DEACETIL-BACCATINA III, ITS DERIVATIVES, THEIR PREPATION AND THERAPEUTIC USE
US5698712A (en) 1992-03-06 1997-12-16 Indena S.P.A. Baccatine III derivatives
FR2688499B1 (en) 1992-03-10 1994-05-06 Rhone Poulenc Rorer Sa PROCESS FOR THE PREPARATION OF BETA-PHENYLISOSERINE AND ITS ANALOGS.
FR2696460B1 (en) 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Process for the preparation of taxane derivatives.
IL107950A (en) 1992-12-15 2001-04-30 Upjohn Co 7β, 8β - METHANO-TAXOLS, THEIR PREPARATION AND ANTINEOPLASTIC PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
CA2111527C (en) 1992-12-24 2000-07-18 Jerzy Golik Phosphonooxymethyl ethers of taxane derivatives
US5475011A (en) 1993-03-26 1995-12-12 The Research Foundation Of State University Of New York Anti-tumor compounds, pharmaceutical compositions, methods for preparation thereof and for treatment
IT1261667B (en) 1993-05-20 1996-05-29 TAX FOR ANTI-CANCER ACTIVITIES.
ES2145829T3 (en) 1993-06-11 2000-07-16 Upjohn Co ANTINEOPLASIC USE OF DELTA 6,7-TAXOLS AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
IL109926A (en) 1993-06-15 2000-02-29 Bristol Myers Squibb Co Methods for the preparation of taxanes and microorganisms and enzymes utilized therein
FR2722191B1 (en) * 1994-07-08 1996-08-23 Rhone Poulenc Rorer Sa PROCESS FOR THE PREPARATION OF (2R, 3S) -3-TERTBUTOXYCARBONYLAMINO-2-HYDROXY-3-PHENYLPROPIONATE (2R, 3S) TRIHYDRATE, 20EPOXY-11BYA -13ALPHA-YLE
IT1275936B1 (en) 1995-03-17 1997-10-24 Indena Spa DERIVATIVES OF 10-DEACETYLBACCATIN III AND OF 10-DEACETYL-14B- HYDROXYBACCATIN III THEIR METHOD OF PREPARATION AND FORMULATIONS
FR2732341A1 (en) 1995-03-27 1996-10-04 Rhone Poulenc Rorer Sa NOVEL TAXOIDS, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
IT1275435B (en) 1995-05-19 1997-08-07 Indena Spa DERIVATIVES OF 10-DESACETYL-14BETA-HYDROXYBACCATIN III, THEIR METHOD OF PREPARATION AND FORMULATIONS CONTAINING THEM
IT1283633B1 (en) 1996-05-10 1998-04-23 Indena Spa TAXANIC DERIVATIVES THEIR SUMMARY AND FORMULATIONS CONTAINING THEM
US5811452A (en) 1997-01-08 1998-09-22 The Research Foundation Of State University Of New York Taxoid reversal agents for drug-resistance in cancer chemotherapy and pharmaceutical compositions thereof
IT1318678B1 (en) 2000-08-10 2003-08-27 Indena Spa PROCEDURE FOR THE PREPARATION OF BACCATIN DERIVATIVES III.
ITMI20012185A1 (en) 2001-10-19 2003-04-19 Indena Spa PROCEDURE FOR THE PREPARATION OF 14BETA-HYDROXY-BACCATIN III-1,14-CARBONATE
ITMI20012186A1 (en) 2001-10-19 2003-04-19 Indena Spa PROCEDURE FOR THE PREPARATION OF 14-BETA-HYDROXY-BACCATIN III-1,14-CARBONATE
WO2005061474A1 (en) 2003-12-12 2005-07-07 Quiral Química Do Brasil Process for the preparation of anhydrous and hydrated active pharmaceutical ingredients (apis); stable pharmaceutical compositions prepared from the same and uses of said compositions
WO2006058121A1 (en) 2004-11-23 2006-06-01 Bristol-Myers Squibb Company Crystalline forms of 3'-tert-butyl-3'-n-tert-butyloxycarbonyl-4-deacetyl-3'-dephenyl-3'-n-debenzoyl-4-o-methoxycarbonyl-paclitaxel
KR100995390B1 (en) * 2006-01-02 2010-11-19 주식회사 삼양제넥스 Method for preparation of amorphous anhydrous crystalline or hydrated crystalline docetaxel
DK1854799T3 (en) 2006-05-12 2011-07-18 Indena Spa Process for preparing a taxane derivative
ES2389518T3 (en) 2008-01-18 2012-10-26 Indena S.P.A. Solid forms of ortataxel

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5367086A (en) * 1992-03-13 1994-11-22 University Of Florida Process for the preparation of taxol and 10-deacetyltaxol
US5319112A (en) * 1992-08-18 1994-06-07 Virgnia Tech Intellectual Properties, Inc. Method for the conversion of cephalomannine to taxol and for the preparation of N-acyl analogs of taxol
US6906101B1 (en) * 1999-07-06 2005-06-14 Indena S.P.A. Taxane derivatives and processes for the preparation thereof
US6737534B2 (en) * 2000-11-28 2004-05-18 Indena S.P.A. Process for the preparation of taxan derivatives
US20070212394A1 (en) * 2006-03-10 2007-09-13 Cook Incorporated Taxane coatings for implantable medical devices
US7232916B1 (en) * 2006-05-11 2007-06-19 Indena S.P.A. Process for the preparation of a taxane derivative

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9127018B2 (en) 2008-01-18 2015-09-08 Indena S.P.A. Solid forms of ortataxel

Also Published As

Publication number Publication date
IL207045A0 (en) 2010-12-30
JP2011509957A (en) 2011-03-31
WO2009090024A1 (en) 2009-07-23
EP2080764B1 (en) 2012-08-22
HK1131782A1 (en) 2010-02-05
DK2080764T3 (en) 2012-09-24
US9127018B2 (en) 2015-09-08
MX2010007850A (en) 2010-11-09
NO342387B1 (en) 2018-05-14
AU2009204559B2 (en) 2013-09-26
EP2080764A1 (en) 2009-07-22
AU2009204559A1 (en) 2009-07-23
RU2488586C2 (en) 2013-07-27
ES2389518T3 (en) 2012-10-26
TWI432437B (en) 2014-04-01
NO20101144L (en) 2010-08-12
US20140128459A1 (en) 2014-05-08
CA2711690C (en) 2017-05-16
TW200936594A (en) 2009-09-01
ZA201004507B (en) 2011-04-28
IL207045A (en) 2014-08-31
BRPI0906698A2 (en) 2015-07-07
CN101952297A (en) 2011-01-19
KR20100102160A (en) 2010-09-20
CA2711690A1 (en) 2009-07-23
RU2010134415A (en) 2012-02-27
AR070185A1 (en) 2010-03-17
KR101583098B1 (en) 2016-01-07

Similar Documents

Publication Publication Date Title
CN103958491B (en) Crystalline dapagliflozin hydrate
TWI364423B (en) Crystal form of asenapine maleate
KR20150140418A (en) Substituted heterocycle fused gamma-carbolines solid
TWI585092B (en) Crystalline (1r,4r)-6'-fluoro-n, n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine
JP2018510914A (en) Method for producing dicycloplatin
US9127018B2 (en) Solid forms of ortataxel
AU2019212668B2 (en) Crystalline forms of mesaconine and preparation method therefor
US20160244420A1 (en) A crystalline anhydrous form of cabazitaxel, process for the preparation and pharmaceutical compositions thereof
JP6276702B2 (en) (1r, 4r) -6'-fluoro-N, N-dimethyl-4-phenyl-4 ', 9'-dihydro-3'H-spiro [cyclohexane-1,1'-pyrano [3,4, b ] Solid form of indole] -4-amine hydrochloride
US20020173648A1 (en) Novel polymorphic forms of cipamfylline
AU2006218133A1 (en) Crystalline forms of (1RS,3RS,6RS)-6-Dimethvlaminomethyl-1-(3-methoxy- phenyl)cyclohexane-1 ,3-diol hydrochloride
EP3473623B1 (en) Crystal forms of nbi-98854, preparation method therefor and use thereof
EP2080763A1 (en) Crystalline form I of ortataxel
CN108659038B (en) Polymorphic substance of 1-stearoyl-2-valoyl-sn-glycerol-3-phosphatidylcholine and preparation method thereof
CN108659037B (en) Polymorphic substance of valproic acid phospholipid derivative and preparation method thereof
CN113801182A (en) Azacitidine crystal form D
HUE029806T2 (en) Solid forms of (1r,4r)-6'-fluoro-(n,n-dimethyl)-4-phenyl-4',9'-dihydro-3'h-spiro-[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and sulfuric acid
AU2011244977A1 (en) Crystalline forms of (1RS,3RS,6RS)-6-Dimethvlaminomethvl-1-(3-methoxv- phenyl)cyclohexane-1 ,3-diol hydrochloride

Legal Events

Date Code Title Description
AS Assignment

Owner name: INDENA S.P.A., ITALY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CICERI, DANIELE;SARDONE, NICOLA;GABETTA, BRUNO;AND OTHERS;REEL/FRAME:024693/0886

Effective date: 20100713

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION